Localized Prostate Cancer: From the Editor
The Road Ahead for Prostate Cancer Disparity
The year 2020 will be remembered for many reasons, few of them good. But among the fires, floods, locusts, and other natural disasters, two tsunamis have swept the country and the world, unequaled in a generation. The first, of course, is the COVID-19 pandemic; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (COVID-19), the other is a groundswell of support for racial justice unequaled in breadth and impact since the civil rights movement over a half-century ago. Both have been met with breathtaking indifference and incompetence by a federal government whose three branches have been rendered virtually powerless by the small-minded machinations of a reactionary minority.
Localized Prostate Cancer: Screening, Risk, Surveillance, and Treatment
As most who find their way to UroToday.com doubtless already know, prostate cancer remains by far the most common non-cutaneous cancer diagnosed, and the second leading cause of cancer death among American men. Worldwide, prostate cancer is steadily rising in both incidence and mortality, with over a 1.1 million new diagnoses and 300,000 deaths annually. In the United States, in the era of PSA-based early detection efforts,
incidence rates have waxed and waned with shifting guidelines and prevalence of PSA testing. Age-adjusted mortality rates have fallen over 50%—the steepest decline of any cancer except lung cancer—and the best statistical models attribute a substantial majority of this decline to screening and to improvements in treatment for localized disease.